| 1 |
35218152 | Establishment and characterization of an immortalized human giant congenital melanocytic nevi cell line. | 2022 May |
1 |
| 2 |
35353498 | Brain-Targeted Codelivery of Bcl-2/Bcl-xl and Mcl-1 Inhibitors by Biomimetic Nanoparticles for Orthotopic Glioblastoma Therapy. | 2022 Mar 30 |
1 |
| 3 |
35406478 | Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins. | 2022 Mar 27 |
1 |
| 4 |
35440079 | Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy. | 2022 Apr 19 |
1 |
| 5 |
32572959 | GSK3β suppression inhibits MCL1 protein synthesis in human acute myeloid leukemia cells. | 2021 Jan |
1 |
| 6 |
33236943 | Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. | 2021 Apr |
1 |
| 7 |
34257274 | Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy. | 2021 Jul 13 |
2 |
| 8 |
34439278 | Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma. | 2021 Aug 17 |
1 |
| 9 |
34603598 | One-Two Punch Therapy for the Treatment of T-Cell Malignancies Involving p53-Dependent Cellular Senescence. | 2021 |
1 |
| 10 |
34667663 | The Role of Navitoclax in Myelofibrosis. | 2021 Sep |
2 |
| 11 |
31907357 | BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells. | 2020 Jan 6 |
1 |
| 12 |
31927215 | Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma. | 2020 Feb |
1 |
| 13 |
32005716 | Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAFV600E-Driven Melanoma. | 2020 Apr 1 |
1 |
| 14 |
32235588 | Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation. | 2020 Mar 30 |
3 |
| 15 |
32247610 | EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-XL inhibitor is overcome by BIM upregulation in ovarian clear cell carcinoma cells. | 2020 Jun 4 |
1 |
| 16 |
32337074 | Endoplasmic reticulum stress mediates resistance to BCL-2 inhibitor in uveal melanoma cells. | 2020 |
1 |
| 17 |
32346617 | Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines. | 2020 Jul |
1 |
| 18 |
32486166 | Albendazole-Induced SIRT3 Upregulation Protects Human Leukemia K562 Cells from the Cytotoxicity of MCL1 Suppression. | 2020 May 30 |
1 |
| 19 |
32511893 | TXNIP induces growth arrest and enhances ABT263-induced apoptosis in mixed-lineage leukemia-rearranged acute myeloid leukemia cells. | 2020 Aug |
1 |
| 20 |
32577785 | Synergistic effects of Bcl-2 inhibitors with AZD9291 on overcoming the acquired resistance of AZD9291 in H1975 cells. | 2020 Sep |
1 |
| 21 |
32687646 | Intracellular levels of reactive oxygen species correlate with ABT-263 sensitivity in non-small-cell lung cancer cells. | 2020 Oct |
2 |
| 22 |
33239070 | Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer. | 2020 Nov 25 |
1 |
| 23 |
33403016 | Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth in vitro. | 2020 |
1 |
| 24 |
33519480 | ABT-263 Reduces Hypertrophic Scars by Targeting Apoptosis of Myofibroblasts. | 2020 |
1 |
| 25 |
30224339 | NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263. | 2019 Jan 1 |
1 |
| 26 |
30526410 | Molecular dynamic simulations on an inhibitor of anti-apoptotic Bcl-2 proteins for insights into its interaction mechanism for anti-cancer activity. | 2019 Aug |
4 |
| 27 |
30679390 | Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. | 2019 Mar |
1 |
| 28 |
30869573 | Combination Treatment with the BRAFV600E Inhibitor Vemurafenib and the BH3 Mimetic Navitoclax for BRAF-Mutant Thyroid Carcinoma. | 2019 Apr |
1 |
| 29 |
30962322 | Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo. | 2019 Jun |
1 |
| 30 |
31222722 | Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma. | 2019 Sep |
1 |
| 31 |
31276572 | Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment. | 2019 |
2 |
| 32 |
31430575 | Importance of Hypericin-Bcl2 interactions for biological effects at subcellular levels. | 2019 Dec |
2 |
| 33 |
31494078 | Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy. | 2019 Nov 5 |
1 |
| 34 |
31881855 | In vitro activity of a G-quadruplex-stabilizing small molecule that synergizes with Navitoclax to induce cytotoxicity in acute myeloid leukemia cells. | 2019 Dec 27 |
1 |
| 35 |
28947240 | Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin. | 2018 Feb |
2 |
| 36 |
29063678 | Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor. | 2018 Mar |
1 |
| 37 |
29580266 | Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines. | 2018 Mar 27 |
1 |
| 38 |
29658609 | Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas. | 2018 Jul |
1 |
| 39 |
29682179 | Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. | 2018 Mar 30 |
1 |
| 40 |
29743557 | Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma. | 2018 May 9 |
1 |
| 41 |
30021909 | Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. | 2018 Nov 1 |
1 |
| 42 |
30185782 | BH3 mimetics induce apoptosis independent of DRP-1 in melanoma. | 2018 Sep 5 |
1 |
| 43 |
27160946 | Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. | 2017 Mar |
1 |
| 44 |
27499136 | HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. | 2017 Feb |
2 |
| 45 |
28079887 | DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis. | 2017 Jan 12 |
1 |
| 46 |
28209992 | From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. | 2017 Apr |
1 |
| 47 |
28273655 | New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. | 2017 Mar 8 |
1 |
| 48 |
28713162 | ABT-263 induces G1/G0-phase arrest, apoptosis and autophagy in human esophageal cancer cells in vitro. | 2017 Dec |
4 |
| 49 |
28714472 | Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. | 2017 Jul 17 |
2 |
| 50 |
29045843 | High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer. | 2017 Oct 17 |
1 |